SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax ...
Sellas Life Sciences to present data from Phase 2a trial of SLS009
SELLAS Life Sciences Group announced that data from its Phase 2a trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia will be presente ...
Dad's devastating fight after losing son to cancer as he says heartbreak 'destroys you'
Peter Colse=on has made 130 trips and covered 125,000 miles across Europe to collect life-saving stem cells after he lost his son James to rare blood cancer myelodysplasia in 2008 ...
The American Journal of Managed Care28d
Access Has Improved for Diverse Patients Needing Umbilical Cord Blood Transplant, but Disparities Remain
2 A transplant procedure has the potential to be lifesaving, especially for individuals with rare conditions like acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), or myelodysplasia ...
eLife2y
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations
This work was supported by Cincinnati Children’s Hospital Research Foundation, Leukemia Lymphoma Society, and National Institute of Health (R35HL135787, RO1HL111103, RO1DK102759, RO1HL114582), ...